Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi in R/R FL and MCL Meet Primary Endpoint of ORR

May 10, 2023

First Results from Ph 2 SunRISe-1 Study of TAR-200 and Cetrelimab in Patients with BCG-Unresponsive NMIBC announced

May 10, 2023

Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME announced

May 10, 2023

Early Positive IMX-110 Interim Data shows 100% Tumor Shrinkage in Advanced mCRC at the Lowest Dose of IMX-110 + Tislelizumab

May 10, 2023

Positive Early Results from Global Randomized Ph 1b/2 Combination Study of TPST-1120 in 1L HCC announced

May 10, 2023

Positive Preliminary Data announced from ADVANCED-1 Ph 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Ph 2 Clinical Development

May 10, 2023

Positive Pivotal Ph 3 SIERRA Trial Results of Iomab-B Announced

May 10, 2023

Positive Ph 3 Tislelizumab Trial in Advanced Gastric or GEJ Adenocarcinoma announced

April 27, 2023

Positive final results from Ph 2 trial of VB10.16 + atezolizumab in advanced cervical cancer announced

April 27, 2023

KEYTRUDA + Chemo Significantly Improved OS Compared to Chemo Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

April 20, 2023

mRNA-4157 (V940) + KEYTRUDA combination Demonstrated Superior RFS in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection vs KEYTRUDA

April 20, 2023

Imfinzi-based treatment before & after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable NSCLC in the AEGEAN Ph 3 trial

April 20, 2023

Positive topline data announced from Part A safety lead-in of THIO-101 Ph 2 trial in advanced NSCLC

April 20, 2023

Tecentriq + Avastin reduced the risk of cancer returning in people with adjuvant HCC at high risk of disease recurrence following liver resection in Ph 3 IMbrave050 study

April 20, 2023

Clinical Data of KEYNOTE-695 Trial of TAVO™-EP + KEYTRUDA in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment announced

April 12, 2023

Lynparza and Imfinzi combination improved PFS in newly diagnosed patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Ph 3 trial

April 12, 2023

FAILED TRIALS: Ph 3 LEAP-003 trial of KEYTRUDA + LENVIMA in 1L metastatic melanoma to be discontinued; combo’s Ph 3 LEAP-017 trial in 1L pMMR mCRC didn’t meet primary endpoint of OS improvement

April 12, 2023

Interim results from Part 1 of Ph 3 RUBY trial of Jemperli + chemo in adult patients with primary advanced or recurrent endometrial cancer announced

April 6, 2023

Ph 3 interim data analysis of RenovoGem therapy for pancreatic cancer patients to be announced

April 6, 2023

Neoadjuvant Opdivo + chemo Demonstrate Long-Term, Durable Clinical Benefits in Resectable NSCLC at 3 Years in the CheckMate -816 Trial

April 6, 2023

Positive Topline Data from BDC-1001 Ph 1 Dose-Escalation Trial in HER2-Expressing Tumors announced, Supporting Advancement to Ph 2 Clinical Studies

April 6, 2023

New RYBREVANT (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced NSCLC with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy

April 6, 2023

Updated Efficacy and Safety of Taletrectinib in Patients with ROS1-Positive NSCLC announced

April 6, 2023

KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced/Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status

April 6, 2023

Results from INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrate Deep and Durable Responses in Platinum Resistant Ovarian Cancer

March 31, 2023
Page1 … Page21 Page22 Page23 Page24 Page25 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.